Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2025-05-21 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) about the allotment of 3,500,000 equity shares to the company's ESOP Trust under the Employee Stock Option and Incentive Plan 2022. It references compliance with SEBI Listing Regulations and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The content focuses on the share allotment event, details of the shares issued, and regulatory disclosures related to the ESOP scheme. There are no financial statements, management discussion, or earnings data presented. The document is an announcement of a capital change event (share allotment under ESOP), not a full report or financial statement. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is under 5,000 characters, but it contains substantive information about the share allotment, not just a report publication announcement. Hence, it is not RPA or RNS. Confidence is high due to clear regulatory references and detailed share issuance data.
2025-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the transcript of a conference call on the audited financial results for the quarter and year ended 31st March 2025. It references the transcript of the conference call held on 15th May 2025 and provides a link to the company's website where the transcript is available. The document itself does not contain the transcript but announces its availability. Given the content and the nature of the document, it is an announcement related to a call transcript rather than the transcript itself. Therefore, the appropriate classification is Call Transcript (CT). However, since the document only announces the transcript and does not contain the full transcript text, it is more accurately classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the transcript availability, not the transcript itself.
2025-05-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the availability of the audio recording of a conference call on the audited financial results for the quarter and year ended 31st March 2025. It references a previous letter and provides a link to the recording on the company's website. The document is short (1449 characters) and serves as an announcement about the conference call recording rather than containing the transcript itself. Therefore, it is not a full Call Transcript (CT) but an announcement related to it. Given the nature of the content and length, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2025-05-15 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation announcing the audited financial results (standalone and consolidated) for the quarter and year ended 31st March 2025. It includes detailed financial highlights, consolidated profit and loss statement, balance sheet, and business segment performance. The document also contains an invitation to an earnings conference call to discuss these results. The content is comprehensive and includes actual financial data and analysis for the quarter and full fiscal year, which aligns with the characteristics of an Interim / Quarterly Report (IR). It is not merely an announcement or a brief summary but a detailed financial report for a period shorter than a full fiscal year (quarter and full year results). Therefore, the appropriate classification is Interim / Quarterly Report (IR). FY 2025
2025-05-14 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation announcing the audited financial results (standalone and consolidated) for the quarter and full year ended 31st March 2025. It includes detailed financial highlights, consolidated profit and loss statement, balance sheet, and business segment performance. The document also contains an invitation to an earnings conference call to discuss these results. The content is comprehensive and includes substantive financial data and analysis for the quarter and full fiscal year, which aligns with the characteristics of an Interim / Quarterly Report (IR) rather than a brief earnings release or just an announcement. The presence of detailed financial statements and management commentary confirms it is a full interim/quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). FY 2025
2025-05-14 English
Resignation
Regulatory Filings
2025-05-14 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.